New York-based Click Therapeutics has closed a Series D round anchored by a USD 50 million strategic investment from Boehringer Ingelheim, alongside additional dedicated commercial funding, to support the commercialization of CT-155, an investigational prescription digital therapeutic device for the experiential negative symptoms of schizophrenia.
The financing accompanies a structural shift in the CT-155 program: Boehringer Ingelheim is transferring full product responsibility — including commercial and marketing authorization rights — to Click. CT-155 was co-developed by the two companies and has not yet received regulatory clearance. Click said proceeds will be directed toward commercialization activities, contingent on US FDA clearance. The Series D follows a Series C strategic investment by Medidata and Dassault Systèmes in 2025, and a USD 52 million Series B in 2021 co-led by H.I.G. BioHealth Partners and Accelmed Partners.
CT-155 received US FDA Breakthrough Device Designation in 2024. The completed Phase III CONVOKE trial (NCT05838625) — a randomized, double-blind, 16-week study evaluating CT-155 versus a digital control app as an adjunct to standard antipsychotic therapy — met its primary endpoint. Treatment with CT-155 produced a 6.8-point improvement in negative symptom severity on the CAINS-MAP scale at 16 weeks, compared with 4.2 points in the digital control arm, representing a 62% relative improvement (Cohen's D effect size of -0.36; p=0.0003). Adverse event rates were 8.3% for CT-155 versus 13.4% for the control arm, with no serious adverse events in either group. A follow-on ENSPIRUS study (NCT06791122), led by Boehringer Ingelheim, is generating real-world effectiveness data and remains active.